Clinical and molecular characterization of Acinetobacter seifertii in Taiwan

Li Hua Li, Ya Sung Yang, Jun Ren Sun, Tzu Wen Huang, Wei Cheng Huang, Feng Jui Chen, Yung Chih Wang, Ting Hao Kuo, Shu Chen Kuo, Te Li Chen, Yi Tzu Lee, Yea Yuan Chang, Ya Sung Yang, Yuag Meng Liu, Shu Chen Kuo, Chang Pan Liu, Te Li Chen, Yi Tzu Lee

研究成果: 雜誌貢獻文章同行評審

8 引文 斯高帕斯(Scopus)


Objectives: Acinetobacter seifertii, a new member of the Acinetobacter baumannii group, has emerged as a cause of severe infections in humans. We investigated the clinical and molecular characteristics of A. seifertii. Patients and methods: This retrospective study enrolled 80 adults with A. seifertii bloodstream infection (BSI) at four medical centres over an 8 year period. Species identification was confirmed by MALDI-TOF MS, rpoB sequencing and WGS. Molecular typing was performed by MLST. Clinical information, antimicrobial susceptibility and the mechanisms of carbapenem and colistin resistance were analysed. Transmissibility of the carbapenem-resistance determinants was examined by conjugation experiments. Results: The main source of A. seifertii BSI was the respiratory tract (46.3%). The 28 day and in-hospital mortality rates of A. seifertii BSI were 18.8% and 30.0%, respectively. High APACHE II scores and immunosuppressant therapy were independent risk factors for 28 day mortality. The most common MLST type was ST553 (58.8%). Most A. seifertii isolates were susceptible to levofloxacin (86.2%), and only 37.5% were susceptible to colistin. Carbapenem resistance was observed in 16.3% of isolates, mostly caused by the plasmid-borne ISAba1-blaOXA-51-like genetic structure. A. seifertii could transfer various carbapenem-resistance determinants to A. baumannii, Acinetobacter nosocomialis and other A. seifertii isolates. Variations of pmrCAB and lpxCAD genes were not associated with colistin resistance of A. seifertii. Conclusions: Levofloxacin and carbapenems, but not colistin, have the potential to be the drug of choice for A. seifertii infections. A. seifertii can transfer carbapenem-resistance determinants to other species of the A. baumannii group and warras close monitoring.
頁(從 - 到)312-321
期刊Journal of Antimicrobial Chemotherapy
出版狀態已發佈 - 2月 1 2021

ASJC Scopus subject areas

  • 藥理
  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)


深入研究「Clinical and molecular characterization of Acinetobacter seifertii in Taiwan」主題。共同形成了獨特的指紋。